Skip to main content
2024 ACRO Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Andreas Rimner, MD (he/him/his)

Vice Chair
Department of Radiation Oncology, University of Freiburg
Loerrach, Baden-Wurttemberg, Germany

Andreas Rimner, MD, is the Vice Chair in the Department of Radiation Oncology at the University of Freiburg, Germany. He was the Director of Thoracic Radiation Oncology Research and an Associate Attending at Memorial Sloan Kettering Cancer Center from 2010 to 2024. He is an international expert specializing in radiation therapy for thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer, malignant pleural mesothelioma (MPM), thymic tumors and metastatic disease. In this role he expanded the thoracic service at MSKCC and led an interdisciplinary team of physicians, physicists and translational scientists. He is an experienced clinical trialists and led more than 10 prospective clinical trials.
Dr. Rimner is the current Vice Chair of the American Radium Society Appropriate Use Criteria Thoracic Committee, an ABR board examiner for Thoracic Cancers and Sarcomas, Board Member of IMIG and Member of the IASLC Staging and Prognostic Factors Committee. He is the Past Thoracic Track Chair of the Annual Meeting of ASTRO, past Vice President of ITMIG, and past member of the lung core committee of NRG Oncology. He was the Principal Investigator of the phase III NRG Oncology trial (NRG LU-006) on the role of hemithoracic pleural IMPRINT in patients with resectable malignant pleural mesothelioma.

Disclosure(s): AstraZeneca: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Boehringer Ingelheim: Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Merck: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024)

Presentation(s):

Email Andreas